A dual label oligonucleotide ligation assay for detection of the CYP2C19*1, CYP2C19*2, and CYP2C19*3 alleles involving time-resolved fluorometry

被引:11
作者
Bathum, L
Hansen, TS
Horder, M
Brosen, K
机构
[1] Odense Univ Hosp, Dept Clin Biochem, DK-5000 Odense C, Denmark
[2] Odense Univ, Dept Clin Pharmacol, DK-5230 Odense, Denmark
关键词
CYP2C19; genotyping; genetic polymorphism;
D O I
10.1097/00007691-199802000-00001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
CYP2C19 (S-mephenytoin hydroxylase) is a polymorphically expressed enzyme. Currently, two defective alleles are known-CYP2C19*2 and CYP2C19*3. The authors have developed an oligonucleotide ligation assay to detect these two alleles. This assay combines the hybridization of one common, biotinylated capture probe and two allele-specific probes to the target DNA, with the ability of a DNA ligase to distinguish mismatched nucleotides. The probes are only ligated if they are base paired correctly to the target strand. The biotin is bound to streptavidin, and all DNA not covalently bound to the biotin-labeled capture probe, is removed in a washing procedure. The allele-specific probes are labeled with either europium or samarium, and their emission can be measured simultaneously. The ratio between the emission separates the genotypes. This method was applied on DNA from 19 whites and 21 Vietnamese living in Denmark. All genotypes determined by the assay were consistent with the results from restriction enzyme cleavage. There were 12 poor metabolizers; 10 homozygous CYP2C19*2/CYP2C19*2, one heterozygous CYP2C19*2/CYP2C19*3, and one heterozygous CYP2C19*1/CYP2C19*2. The authors conclude that this assay is well-suited for a high throughput of samples in a routine laboratory. The finding of an apparently heterozygous CYP2C19*1/CYP2C19*2 poor metabolizer, confirms that there are still unknown mutations in CYP2C19.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 25 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[3]   IMPORTANCE OF GENETIC-FACTORS IN THE REGULATION OF DIAZEPAM METABOLISM - RELATIONSHIP TO S-MEPHENYTOIN, BUT NOT DEBRISOQUIN, HYDROXYLATION PHENOTYPE [J].
BERTILSSON, L ;
HENTHORN, TK ;
SANZ, E ;
TYBRING, G ;
SAWE, J ;
VILLEN, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 45 (04) :348-355
[4]  
BLISS C, 1967, STAT BIOL, P348
[5]   ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES [J].
BREYERPFAFF, U ;
PFANDL, B ;
NILL, K ;
NUSSER, E ;
MONNEY, C ;
JONZIERPEREY, M ;
BAETTIG, D ;
BAUMANN, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :350-358
[6]   PROGUANIL METABOLISM IS DETERMINED BY THE MEPHENYTOIN OXIDATION POLYMORPHISM IN VIETNAMESE LIVING IN DENMARK [J].
BROSEN, K ;
SKJELBO, E ;
FLACHS, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (02) :105-108
[7]   A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE [J].
BROSEN, K ;
DEMORAIS, SMF ;
MEYER, UA ;
GOLDSTEIN, JA .
PHARMACOGENETICS, 1995, 5 (05) :312-317
[8]  
DAHLEN P, 1993, CLIN CHEM, V39, P1626
[9]  
DELAHUNTY CM, 1995, CLIN CHEM, V41, P59
[10]  
DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594